Alx Oncology Holdings Stock Total Debt
| ALXO Stock | USD 0.74 0.04 5.13% |
Alx Oncology Holdings fundamentals help investors to digest information that contributes to Alx Oncology's financial success or failures. It also enables traders to predict the movement of Alx Stock. The fundamental analysis module provides a way to measure Alx Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alx Oncology stock.
As of the 19th of March 2025, Total Debt To Capitalization is likely to drop to 0. Alx | Total Debt |
Alx Oncology Holdings Company Total Debt Analysis
Alx Oncology's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Alx Oncology Total Debt | 435 K |
Most of Alx Oncology's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alx Oncology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alx Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Alx Oncology is extremely important. It helps to project a fair market value of Alx Stock properly, considering its historical fundamentals such as Total Debt. Since Alx Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alx Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alx Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Alx Total Debt Historical Pattern
Today, most investors in Alx Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alx Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Alx Oncology total debt as a starting point in their analysis.
Alx Oncology Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Alx Net Debt
Based on the latest financial disclosure, Alx Oncology Holdings has a Total Debt of 435 K. This is 99.98% lower than that of the Biotechnology sector and 99.87% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.
Alx Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alx Oncology's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alx Oncology could also be used in its relative valuation, which is a method of valuing Alx Oncology by comparing valuation metrics of similar companies.Alx Oncology is currently under evaluation in total debt category among its peers.
Alx Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Alx Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alx Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alx Oncology's value.| Shares | Bank Of Montreal | 2024-12-31 | 826.6 K | Bmo Capital Markets Corp. | 2024-12-31 | 826.6 K | Two Sigma Advisers, Llc | 2024-12-31 | 823.9 K | Geode Capital Management, Llc | 2024-12-31 | 740.1 K | Two Sigma Investments Llc | 2024-12-31 | 704.1 K | State Street Corp | 2024-12-31 | 684.1 K | Goldman Sachs Group Inc | 2024-12-31 | 569 K | Privium Fund Management B.v. | 2024-12-31 | 509.1 K | Ubs Group Ag | 2024-12-31 | 408.1 K | Venbio Partners Llc | 2024-12-31 | 9.7 M | Redmile Group, Llc | 2024-12-31 | 3.7 M |
Alx Fundamentals
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (76.02 M) | ||||
| Shares Outstanding | 53.38 M | ||||
| Shares Owned By Insiders | 2.03 % | ||||
| Shares Owned By Institutions | 89.35 % | ||||
| Number Of Shares Shorted | 6.45 M | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 5,906 X | ||||
| Gross Profit | 107 K | ||||
| EBITDA | (132.25 M) | ||||
| Net Income | (134.85 M) | ||||
| Cash And Equivalents | 313.37 M | ||||
| Cash Per Share | 7.69 X | ||||
| Total Debt | 435 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.23 X | ||||
| Book Value Per Share | 2.14 X | ||||
| Cash Flow From Operations | (121.91 M) | ||||
| Short Ratio | 8.93 X | ||||
| Earnings Per Share | (2.58) X | ||||
| Target Price | 2.93 | ||||
| Number Of Employees | 80 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 41.83 M | ||||
| Total Asset | 147.78 M | ||||
| Retained Earnings | (621.12 M) | ||||
| Working Capital | 115.85 M | ||||
| Net Asset | 147.78 M |
About Alx Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alx Oncology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alx Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alx Oncology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Alx Stock
Moving against Alx Stock
| 0.88 | VALN | Valneva SE ADR | PairCorr |
| 0.7 | VIGL | Vigil Neuroscience | PairCorr |
| 0.7 | DVAX | Dynavax Technologies | PairCorr |
| 0.59 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.56 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alx Oncology Piotroski F Score and Alx Oncology Altman Z Score analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.